180 related articles for article (PubMed ID: 27236149)
1. Meta-analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation.
Yang C; Qin B; Yuan Z; Chen L; Zhou HY
Ann Hepatol; 2016; 15(4):501-11. PubMed ID: 27236149
[TBL] [Abstract][Full Text] [Related]
2. Comparison of entecavir and lamivudine in preventing HBV reactivation in lymphoma patients undergoing chemotherapy: a meta-analysis.
Yu S; Luo H; Pan M; Luis AP; Xiong Z; Shuai P; Zhang Z
Int J Clin Pharm; 2016 Oct; 38(5):1035-43. PubMed ID: 27450506
[TBL] [Abstract][Full Text] [Related]
3. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
Chen FW; Coyle L; Jones BE; Pattullo V
Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
[TBL] [Abstract][Full Text] [Related]
4. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation.
Zhang MY; Zhu GQ; Shi KQ; Zheng JN; Cheng Z; Zou ZL; Huang HH; Chen FY; Zheng MH
Oncotarget; 2016 May; 7(21):30642-58. PubMed ID: 27121321
[TBL] [Abstract][Full Text] [Related]
5. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
[TBL] [Abstract][Full Text] [Related]
6. Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
Zhang MY; Zhu GQ; Zheng JN; Cheng Z; Van Poucke S; Shi KQ; Huang HH; Chen FY; Zheng MH
Expert Rev Anti Infect Ther; 2017 May; 15(5):503-513. PubMed ID: 28317397
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of Entecavir and Lamivudine for the Prophylaxis of Hepatitis B Virus Reactivation in Solid Tumor Patients Undergoing Systemic Cytotoxic Chemotherapy.
Chen WC; Cheng JS; Chiang PH; Tsay FW; Chan HH; Chang HW; Yu HC; Tsai WL; Lai KH; Hsu PI
PLoS One; 2015; 10(6):e0131545. PubMed ID: 26121480
[TBL] [Abstract][Full Text] [Related]
8. [Reactivation of chronic hepatitis B].
Šperl J
Vnitr Lek; 2013 Jul; 59(7):591-6. PubMed ID: 23909265
[TBL] [Abstract][Full Text] [Related]
9. Entecavir versus lamivudine for the treatment of chronic hepatitis B: a systematic review.
Liang J; Tang YF; Wu FS; Deng X
Pharmazie; 2012 Nov; 67(11):883-90. PubMed ID: 23210236
[TBL] [Abstract][Full Text] [Related]
10. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection.
Kohrt HE; Ouyang DL; Keeffe EB
Clin Liver Dis; 2007 Nov; 11(4):965-91, x. PubMed ID: 17981237
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of nucleos(t)ide analogues in chronic hepatitis B patients undergoing cytotoxic chemotherapy.
Tseng CM; Chen TB; Hsu YC; Chang CY; Lin JT; Mo LR
Asia Pac J Clin Oncol; 2016 Dec; 12(4):421-429. PubMed ID: 27435683
[TBL] [Abstract][Full Text] [Related]
12. Entecavir as a first-line treatment for hepatitis B virus reactivation following polychemotherapy for chronic lymphocytic leukemia and invasive ductal carcinoma: a report of two cases and review of the literature.
Türker K; Albayrak M; Öksüzoğlu B; Balc E; Oğan MC; Iskender G; Altuntaş F
Eur J Gastroenterol Hepatol; 2015 Jan; 27(1):39-45. PubMed ID: 25076063
[TBL] [Abstract][Full Text] [Related]
13. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy.
Loomba R; Rowley A; Wesley R; Liang TJ; Hoofnagle JH; Pucino F; Csako G
Ann Intern Med; 2008 Apr; 148(7):519-28. PubMed ID: 18378948
[TBL] [Abstract][Full Text] [Related]
14. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.
Yeo W; Ho WM; Hui P; Chan PK; Lam KC; Lee JJ; Johnson PJ
Breast Cancer Res Treat; 2004 Dec; 88(3):209-15. PubMed ID: 15609123
[TBL] [Abstract][Full Text] [Related]
15. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
[TBL] [Abstract][Full Text] [Related]
16. Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients.
Dienstag JL; Wei LJ; Xu D; Kreter B
Clin Drug Investig; 2007; 27(1):35-49. PubMed ID: 17177578
[TBL] [Abstract][Full Text] [Related]
17. Antiviral prophylaxis during chemotherapy or immunosuppressive drug therapy to prevent HBV reactivation in patients with resolved HBV infection: a systematic review and meta-analysis.
Su YC; Lin PC; Yu HC; Wu CC
Eur J Clin Pharmacol; 2018 Sep; 74(9):1111-1119. PubMed ID: 29845351
[TBL] [Abstract][Full Text] [Related]
18. [The efficacy of lamivudine in the treatment of reactivation of chronic hepatitis B virus infection in patients on immunosuppressive therapy].
Popović N; Stojković-Švirtlih N; Simonović-Babić J; Boričić I; Tomanović N; Mitrović N; Delić D
Srp Arh Celok Lek; 2011; 139(11-12):824-7. PubMed ID: 22338485
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: a meta-analysis.
Liu JY; Sheng YJ; Ding XC; Tang H; Tong SW; Zhang DZ; Zhou Z; Hu P; Liao Y; Ren H; Hu HD
J Formos Med Assoc; 2015 Feb; 114(2):164-73. PubMed ID: 25678179
[TBL] [Abstract][Full Text] [Related]
20. Entecavir for the treatment of chronic hepatitis B virus infection.
Matthews SJ
Clin Ther; 2006 Feb; 28(2):184-203. PubMed ID: 16678641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
